| Bioactivity | CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1]. | ||||||||||||
| Invitro | CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC50 values less than 0.5 µM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC50 value of 0.837 µM[1]. | ||||||||||||
| Name | CDK9-IN-7 | ||||||||||||
| CAS | 2369981-71-3 | ||||||||||||
| Formula | C29H37N7O2S | ||||||||||||
| Molar Mass | 547.71 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
CDK9-IN-7
CAS: 2369981-71-3 F: C29H37N7O2S W: 547.71
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which ex
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.